In a season when several much-anticipated heart medicines have stumbled, Novartis has learned that its drug aimed at lipoprotein(a), a stubborn blood particle long suspected of driving heart disease, did not prevent heart attacks or strokes in its major trial. The result matters beyond one company, because the same biological idea is being pursued by Amgen and Eli Lilly, and the field must now ask whether a promising theory has truly reached the patients it was meant to help. Such moments remind medicine that a plausible target and a strong reputation are not the same as a proven outcome.
Two High-Profile Heart Drugs Fail, Prompting Calls for Skepticism Toward AI-Driven Drug Hype
The 'slam dunk' that wasn't
Mark
Start with the basics. What actually failed here?
Mimi
A Novartis drug that lowers Lp(a), a blood particle tied to heart disease. In its major trial it didn't prevent heart attacks or strokes. Fierce Biotech's wording was zero benefit.
Mark
Why is that such a shock?
Mimi
The coverage keeps using words like unexpectedly and stunning, and NBC called it a slam dunk that wasn't. Expectations were high.
Luke
Careful, though. Those are headlines. We have the verdict, no trial numbers, no patient counts, no confidence intervals.
Mark
Fair. Does it hurt Amgen and Lilly?
Mimi
Fierce Biotech says it casts a shadow over their programs. They're working on the same target.
Luke
A shadow isn't a result. Their drugs and trials may differ, and nothing here says they've failed.
Mark
The Times mentions two drugs. What's the second?
Luke
That isn't in what we have. I'd not guess.
Mimi
And STAT ties all this to AI hype, which is its argument, not a finding from the trial.
Luke
Right. The link to AI is opinion we can't evaluate from a headline.
El Pulso
- A major Novartis trial of its Lp(a)-lowering drug found no reduction in heart attacks or strokes, a blow that landed hard on a field that had expected more.
- Headlines describing the result as a 'slam dunk' that wasn't, and a 'stunning failure,' show how sharply high expectations have collided with the data.
- Two high-profile heart drug setbacks are being read together as a pattern, sending doctors and analysts back to question how promising cardiac therapies are judged.
- Amgen and Eli Lilly, which have their own Lp(a) programs, now face the question of whether their trials will repeat the outcome or differ from it.
- The field is waiting on those upcoming trial results to decide whether this is a verdict on one drug or on the entire Lp(a) approach.
In a season when several much-anticipated heart medicines have stumbled, Novartis has learned that its drug aimed at lipoprotein(a), a stubborn blood particle long suspected of driving heart disease, did not prevent heart attacks or strokes in its major trial. The result matters beyond one company, because the same biological idea is being pursued by Amgen and Eli Lilly, and the field must now ask whether a promising theory has truly reached the patients it was meant to help. Such moments remind medicine that a plausible target and a strong reputation are not the same as a proven outcome.
A cluster of headlines has turned a difficult week in cardiology into a moment of reckoning. Novartis, whose cholesterol-related drug targets lipoprotein(a), a blood particle linked to heart disease, reported that the medicine did not prevent heart attacks or strokes in its major trial. Fierce Biotech put it plainly: zero clinical benefit. For a drug that many had regarded as promising, the outcome has been received as a genuine surprise, and NBC's phrase 'slam dunk' that wasn't captures how far expectations had run ahead of the evidence.
The stakes reach past Novartis. Amgen and Eli Lilly are also developing Lp(a) treatments, and coverage suggests this result casts a shadow over those programs. If lowering the particle did not change outcomes here, the others must show whether their own drugs and trials will tell a different story.
The New York Times refers to two high-profile heart drugs, and the failures are being treated as a pattern rather than a single disappointment. STAT takes the discussion further, linking the setbacks to the enthusiasm surrounding artificial intelligence in drug development, though that argument is an editorial position rather than a trial finding. The central fact remains simple: the trial measured heart attacks and strokes, and the Novartis drug did not reduce them.
The headlines gathered in a single Google News cluster read like a run of bad news for cardiology. STAT asks why the latest heart drug failures should make readers more skeptical of AI hype. NPR reports that a promising new medicine against heart disease failed unexpectedly. The New York Times says doctors are absorbing the stunning failure of two high-profile heart drugs. NBC News calls it the 'slam dunk' that wasn't.
The center of the story is a cholesterol-related drug from Novartis that targets Lp(a), a particle in the blood linked to heart disease risk. According to the coverage, the drug did not prevent heart attacks or strokes in its major trial. Fierce Biotech put it most bluntly, reporting that the Novartis drug showed zero benefit.
The finding matters because Novartis is not the only company working on this approach. Fierce Biotech reports that the result casts a shadow over Lp(a) programs at Amgen and Eli Lilly. If lowering Lp(a) did not change outcomes for patients in the Novartis trial, the question for the other companies is whether their own drugs, and their own trials, will land anywhere different.
The word 'slam dunk' in the NBC headline signals how high expectations had been. The coverage describes a drug that was widely seen as promising, which is part of why the result is landing so hard. NPR's phrasing, 'unexpectedly,' and the Times' phrase 'stunning failure' point the same way: this was not a trial many in the field expected to come up empty.
The Times headline refers to two high-profile heart drugs, not one. The material available here does not identify the second drug or describe its trial, so the full scope of the setback cannot be laid out from these headlines alone. What the cluster does establish is that the failures are being treated as a pattern worth noting, not an isolated disappointment.
STAT takes the argument in a different direction. Its headline links the failures to the enthusiasm around artificial intelligence in drug development, suggesting that the same kind of confident expectation surrounding AI-driven medicine deserves a harder look. The headline itself is all that is available, so the details of STAT's reasoning are not something this account can reproduce. The framing is an editorial argument, not a trial result.
The practical point for readers is that a plausible biological target, a well-regarded drug, and strong expectations did not add up to fewer heart attacks or strokes. Those outcomes are what the trial was built to measure, and on them the Novartis drug showed no benefit.
What to watch next is how the Amgen and Lilly Lp(a) programs respond. Whether their trials confirm the Novartis outcome or diverge from it will determine if this is a verdict on one drug or on the whole approach.
Citas Notables
The Novartis Lp(a) drug shows zero benefit, casting a shadow over Amgen and Lilly programs.— Fierce Biotech headline
Quieres la nota completa?
Lee el original en Google News ↗
Health & Medicine